Indemnification AgreementIndemnification Agreement • April 1st, 2024 • AgeX Therapeutics, Inc. • Pharmaceutical preparations • Delaware
THIS INDEMNIFICATION AGREEMENT (as amended, restated or otherwise modified from time to time in accordance with its terms, the “Agreement”) is made and entered into as of March [●], 2024 between Serina Therapeutics, Inc., a Delaware corporation (the “Company”), and [●] (“Indemnitee”).
AMENDED AND RESTATED CONVERTIBLE PROMISSORY NOTEAgeX Therapeutics, Inc. • April 1st, 2024 • Pharmaceutical preparations • New York
This Allonge and Seventh Amendment to Amended and Restated Convertible Promissory Note (this “Amendment”) by and between AgeX Therapeutics, Inc., a Delaware corporation (“Borrower”), the Guarantors party hereto, and Juvenescence Limited, a company incorporated in the Isle of Man (“Lender”) is effective as of March 26, 2024 (“Effective Date”).
FORM OF NON-QUALIFIED STOCK OPTION AGREEMENTForm of Non-Qualified Stock Option Agreement • April 1st, 2024 • AgeX Therapeutics, Inc. • Pharmaceutical preparations • Delaware
THIS NON-QUALIFIED STOCK OPTION AGREEMENT (the “Agreement”) is made and entered into effective as of_________, 20XX (the “Grant Date”), by and between Serina Therapeutics, Inc., a Delaware corporation (the “Company”), and _________ (“Participant”), an Employee, Consultant, or Director (as such terms are defined in the Plan) of the Company or of a subsidiary of the Company (hereinafter included within the term “Company”) within the meaning of Section 424(f) of the Internal Revenue Code of 1986, as amended (the “Code”).
ASSET CONTRIBUTION AGREEMENTAsset Contribution Agreement • April 1st, 2024 • AgeX Therapeutics, Inc. • Pharmaceutical preparations • Delaware
THIS ASSET CONTRIBUTION AGREEMENT (this “Agreement”) is entered into as of March 26, 2024 (the “Effective Date”), by and between AgeX Therapeutics, Inc., a Delaware corporation (“AgeX”), and UniverXome Bioengineering, Inc., a Delaware corporation (“UniverXome”). Certain capitalized terms used in this Agreement are defined in Exhibit A.
AGREEMENT WITH RESPECT TO CONVERTIBLE NOTES March 26, 2024 (the “Effective Date”)AgeX Therapeutics, Inc. • April 1st, 2024 • Pharmaceutical preparations
WHEREAS, AgeX Therapeutics, Inc., a Delaware corporation (the “AgeX”), is the Borrower referenced in that certain Secured Convertible Promissory Note, dated February 14, 2022 payable to Juvenescence Limited, a company incorporated in the Isle of Man (the “Holder”), as modified by that certain Amended and Restated Secured Convertible Promissory Noted dated February 9, 2023, that certain First Amendment to Amended and Restated Convertible Promissory Note, dated March 13, 2023, that certain Allonge and Second Amendment to Amended and Restated Convertible Promissory Note, dated as of May 9, 2023, that certain Third Amendment to Amended and Restated Convertible Promissory Note, dated as of June 2, 2023, that certain Fourth Amendment to Amended and Restated Convertible Promissory Note, dated as of July 21, 2023, that certain Allonge and Fifth Amendment to Amended and Restated Convertible Promissory Note, dated November 9, 2023, that certain Sixth Amendment to Amended and Restated Convertible
